Investor Presentation First Nine Months of 2023

134 North America Operations growth has accelerated Investor presentation First nine months of 2023 DKK billion 1% 100 60 80 60 60 40 40 20 20 NAO 21% 49% 94 91 North America Operations reported sales growth per therapy area 3% 14% 67 60 60 61 0 2019 CER: Constant exchange rate; 9M: 9 months 2020 2021 GLP-1 Insulin Other diabetes Obesity care Rare disease 2022 Growth at CER 9M 2023

View entire presentation